Reliq Health Technologies - CEO Dr. Lisa Crossley
CEO Dr. Lisa Crossley
Source: Reliq Health Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Reliq Health Technologies (RHT) has signed new contracts with four physician practices in California and Texas to add over 5,000 new patients to its platform
  • Reliq has gone live with the first client through its partnership agreement with Data Soft Logic
  • Onboarding with Data Soft Logic is expected to add over 50,000 patients per year to Reliq’s iUGO Care platform
  • Data Soft Logic Corporation is a cloud-based home health care and Hospice solution
  • Reliq Health Technologies specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring
  • Reliq Health Technologies Inc. (RHT) opened trading at C$0.40 per share

Reliq Health Technologies (RHT) has signed new contracts with four physician practices in California and Texas to add over 5,000 new patients to its platform.

The company is also pleased to announce that it has gone live with the first client through its partnership agreement with Data Soft Logic. Onboarding with Data Soft Logic is expected to ramp up over the remainder of 2022, adding over 50,000 patients per year to Reliq’s iUGO Care platform in 2023 and beyond.

Dr. Lisa Crossley, CEO at Reliq Health Technologies, commented on the news.

“We are pleased to be adding four new physician practices in California and Texas. Together these clients are expected to add over 5,000 patients to our platform in the next nine months at an average revenue of $50 per patient per month at 75% gross margin. Onboarding with these clients is expected to begin next month.”

Dr. Crossley added,

“We are also very excited to have gone live with our first client through our partnership with Data Soft Logic. Onboarding has already begun with the client. Data Soft Logic is a provider of cloud-based home health and hospice care solutions that include point of care, billing, scheduling, accounting and human resources applications. Their solutions are currently used by over 600 home health and hospice care agencies across the United States. Data Soft Logic’s home health and hospice clients work with over 1,000 primary care physicians who provide care to over 500,000 Medicare and Medicaid patients. As previously disclosed, the Company expects to add over 50,000 patients per year to the platform beginning in 2023 through the partnership with Data Soft Logic, at an average revenue of $60 per patient per month (at 75% gross margin). Reliq remains on track to have over 100,000 patients on our iUGO Care platform by December 31, 2022.”

Data Soft Logic Corporation is a cloud-based home health care and Hospice solution offering a suite of applications including Point of Care, Symptom Management, Billing, Scheduling, Accounting and Human Resources.

Reliq Health Technologies specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring, telemedicine, and care collaboration. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

Reliq Health Technologies Inc. (RHT) opened trading at C$0.40 per share.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.